Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T22:47:59.460Z.
Calculation as of: 2026-10-06T22:47:59.460Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2fc0b38e6dc372860fd9bea61ccff40ee6de978c8f50a2bbdf53c6942eb71849
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$7.31M
EV/Sales Ratio
0.00x
TTM Avg
0.29x
3Y Avg
0.29x
5Y Avg
1.64x
Market Cap
$7.64M
EV/Sales Ratio
24.52x
TTM Avg
19.77x
3Y Avg
15.30x
5Y Avg
133.58x
Market Cap
$7.67M
EV/Sales Ratio
N/A
TTM Avg
1162726.42x
3Y Avg
640219.29x
5Y Avg
640219.29x
Market Cap
$7.19M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.19M
EV/Sales Ratio
7.40x
TTM Avg
5.17x
3Y Avg
3.61x
5Y Avg
2.57x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | $7.46M | N/A | N/A | N/A | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | 0.00x | 0.29x | 0.29x | 1.64x |
| Mangoceuticals, Inc. (MGRX)vs › | $7.64M | 24.52x | 19.77x | 15.30x | 133.58x |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.67M | N/A | 1162726.42x | 640219.29x | 640219.29x |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.19M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $7.19M | 7.40x | 5.17x | 3.61x | 2.57x |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | N/A | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.15M | N/A | 5.06x | 10.00x | 33.75x |
| Skye Bioscience, Inc. (SKYE)vs › | $7.12M | N/A | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.07M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
